Practicability of pharmacogenetics in transplantation medicine

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 3, 2014, Pages 262-264

  Van Gelder, T ^a   Van Schaik, R H ^a   Hesselink, D A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P-450 CYP3A; DRUG MONITORING; GENOTYPE; GLUCURONOSYLTRANSFERASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; ORGAN TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84894495775     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.169     Document Type: Article

References (5)

1. Hesselink, D.A. et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254 (2003).
2. MacPhee, I.A. et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4, 914-919 (2004).
3. Thervet, E. et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87, 721-726 (2010).
4. Naesens, M., Lerut, E., de Jonge, H., Van Damme, B., Vanrenterghem, Y., Kuypers, D.R. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol. 20, 2468-2480 (2009).
5. van Schaik, R.H. et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86, 319-327 (2009).